Get the Stockscreener App
18.05
0.39%
0.07
Bausch Lomb Corp stock is traded at $18.05, with a volume of 353.29K.
It is up +0.39% in the last 24 hours and up +9.06% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$17.98
Open:
$18.2
24h Volume:
353.29K
Relative Volume:
0.93
Market Cap:
$6.40B
Revenue:
$5.10B
Net Income/Loss:
$-352.00M
P/E Ratio:
-17.72
EPS:
-1.0189
Net Cash Flow:
$-66.14M
1W Performance:
-2.96%
1M Performance:
+9.06%
6M Performance:
+23.71%
1Y Performance:
+13.95%
1-Day Range:
$17.82
$18.20
1-Week Range:
$17.48
$18.61
52-Week Range:
$10.45
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
18.05 | 6.37B | 5.10B | -352.00M | -66.14M | -1.0189 |
|
ISRG
Intuitive Surgical Inc
|
501.18 | 176.65B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.49 | 49.56B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
84.27 | 40.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
259.05 | 37.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
42.88 | 36.02B | 28.43B | 1.16B | 1.26B | 1.4457 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Director adds BLCO stake with 4,500-share buy and 4,500 RSUs grant - Stock Titan
Insider Buying: Eduardo Alfonso Acquires Shares of Bausch & Lomb Corp (BLCO) - GuruFocus
[Form 4] Bausch & Lomb Corp Insider Trading Activity - Stock Titan
Bausch & Lomb (NYSE: BLCO) director buys shares, gets RSUs - Stock Titan
BLCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP disposes shares for taxes - Stock Titan
Bausch & Lomb (BLCO) officer has shares withheld for RSU tax - Stock Titan
Tax-withholding share moves by Bausch & Lomb (NYSE: BLCO) executive - Stock Titan
Bausch & Lomb (BLCO) EVP uses share withholding to cover tax on RSU vesting - Stock Titan
Bausch & Lomb (BLCO) EVP uses shares for tax withholding on RSU vesting - Stock Titan
CFO tax share withholding at Bausch & Lomb (BLCO) after RSU vesting - Stock Titan
Bausch & Lomb (BLCO) CEO uses common shares to cover RSU tax - Stock Titan
Bausch & Lomb (BLCO) SVP awarded 18,253 restricted share units in Form 4 - Stock Titan
Executive at Bausch & Lomb (NYSE: BLCO) granted 32,710 restricted share units - Stock Titan
Bausch & Lomb (NYSE: BLCO) EVP awarded 35,046 restricted share units - Stock Titan
327,102-share RSU award to Bausch & Lomb (BLCO) CEO Brent Saunders - Stock Titan
Bausch + Lomb Corp. Hits New 52-Week High at $18.91 - Markets Mojo
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth - Insider Monkey
BLCO Should I Buy - Intellectia AI
Bausch + Lomb stock hits 52-week high at $18.86 By Investing.com - Investing.com Canada
Bausch & Lomb (BLCO) CEO uses 65,444 shares to cover tax withholding - Stock Titan
Bausch + Lomb stock hits 52-week high at $18.86 - Investing.com South Africa
Is Expert Backing Of LUMIFY’s Safety Profile Quietly Shaping Bausch + Lomb’s Consumer Strategy (BLCO)? - simplywall.st
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036 - GlobeNewswire Inc.
5 Revealing Analyst Questions From Bausch + Lomb's Q4 Earnings Call - Finviz
Director Steven Collis adds BLCO stake with 15,000-share buy and RSU grant - Stock Titan
Director boosts Bausch & Lomb (BLCO) stake with share buy and matching RSUs - Stock Titan
Is It Time To Reassess Bausch + Lomb (BLCO) After Its Recent Share Price Strength? - Yahoo Finance
H.C. Wainwright raises Bausch & Lomb stock price target to $20 - Investing.com South Africa
Bausch + Lomb Corporation - Baystreet.ca
H.C. Wainwright raises Bausch & Lomb stock price target to $20 By Investing.com - Investing.com Canada
HC Wainwright Comments on Bausch + Lomb Q1 Earnings - MarketBeat
Digital lifestyles are turning eyes red – and one drop stands out - Stock Titan
Adding B Vitamins To AREDS Has Bausch + Lomb Seeing Consumer Health Sales Boost Ahead - Citeline News & Insights
Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook - Insider Monkey
Director Karen Ling adds Bausch & Lomb (BLCO) shares and gets 4,000 RSUs - Stock Titan
Director receives 5,255 RSUs at Bausch & Lomb (NYSE: BLCO) - Stock Titan
Bausch & Lomb (BLCO) awards 5,255 RSUs to director - Stock Titan
Director at Bausch & Lomb (BLCO) receives 1,451 restricted share units - Stock Titan
Director John Paulson granted 1,239 Bausch & Lomb (BLCO) restricted share units - Stock Titan
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $20 - 富途牛牛
Market Rankings: Is BSBK benefiting from innovation trendsJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn
Bausch & Lomb (NYSE: BLCO) EVP earns 29,406 performance-based shares - Stock Titan
Stifel raises Bausch & Lomb stock price target on strong Miebo sales - Investing.com South Africa
Deutsche Bank Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $18 - 富途牛牛
Bausch + Lomb price target raised to $15 from $13 at BofA - TipRanks
Breaking Down Bausch & Lomb: 6 Analysts Share Their Views - Benzinga
Bausch + Lomb price target raised to $21 from $20 at Citi - TipRanks
Bausch + Lomb (BLCO) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):